Advanced Search Results For "Androstadienes"
Your filters
Metabolomic changes related to airway inflammation, asthma pathogenesis and systemic activity following inhaled fluticasone furoate/vilanterol: a randomized controlled trial.
Publication Type: Academic Journal
Source(s): Respiratory research [Respir Res] 2022 Sep 20; Vol. 23 (1), pp. 258. Date of Electronic Publication: 2022 Sep 20.
Abstract: Background: Fluticasone furoate/vilanterol trifenatate (FF/VI) is an inhaled therapy for the treatment of asthma, with a prolonged duration of anti-inflammatory and bronchodilatory action. This study investigated the global metabolomic and lipidomic pr...
Corticosteroid treatment attenuates anxiety and mPFC-amygdala circuit dysfunction in allergic asthma.
Publication Type: Academic Journal
Source(s): Life sciences [Life Sci] 2023 Feb 15; Vol. 315, pp. 121373. Date of Electronic Publication: 2023 Jan 05.
Abstract: Aims: Allergic asthma is associated with anxiety-related behaviors, leading to poor quality of life. Previous studies mainly described the neuropathophysiology of asthma-induced anxiety. However, the effects of corticosteroids, the most common anti-inf...
In Vitro Drug Delivery of a Fixed-Dose Combination of Fluticasone Furoate/Umeclidinium/Vilanterol from a Dry Powder Inhaler.
Publication Type: Academic Journal
Source(s): Journal of aerosol medicine and pulmonary drug delivery [J Aerosol Med Pulm Drug Deliv] 2023 Feb; Vol. 36 (1), pp. 34-43. Date of Electronic Publication: 2023 Jan 25.
Abstract: Background: Dry powder inhalers (DPIs) require patients to impart sufficient energy through inhalation to ensure adequate dose emission, medication deaggregation, and resultant particle sizes suitable for lung deposition. There is an ongoing d...
Fluticasone furoate plus vilanterol in patients with moderate persistent asthma: a cost-utility analysis.
Publication Type: Academic Journal
Source(s): The Journal of asthma : official journal of the Association for the Care of Asthma [J Asthma] 2023 Feb; Vol. 60 (2), pp. 377-384. Date of Electronic Publication: 2022 Mar 17.
Abstract: Background: In recent years, the combination of fluticasone furoate and vilanterol (FF/VI) has emerged as an alternative therapy, since it is administered every 24 h, in contrast to other ICS/LABAs such as fluticasone propionate plus salmeterol (FP/Sal...
Olopatadine/mometasone (Ryaltris) for allergic rhinitis.
Publication Type: Academic Journal
Source(s): The Medical letter on drugs and therapeutics [Med Lett Drugs Ther] 2023 Jan 23; Vol. 65 (1668), pp. 12-14.
How do we manage asthma? Assessment of knowledge, attitude, and practice patterns among pulmonologists and allergists.
Publication Type: Academic Journal
Source(s): The Journal of asthma : official journal of the Association for the Care of Asthma [J Asthma] 2023 Jan; Vol. 60 (1), pp. 130-138. Date of Electronic Publication: 2022 Feb 03.
Abstract: Objective: The objective of this study was to evaluate and compare knowledge, attitude, and practice patterns between pulmonologists and allergists for adult asthma in Turkey. Methods: Questionnaire-based data were gathere...
Fluticasone furoate: CAPTAIN of fluticasones in type 2 inflammatory asthma.
Publication Type: Report
Source(s): Respirology (Carlton, Vic.) [Respirology] 2022 Mar; Vol. 27 (3), pp. 184-186. Date of Electronic Publication: 2022 Feb 01.
Real-Life Analysis of Efficacy and Safety of Everolimus Plus Exemestane in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor-2-Negative Metastatic Breast Cancer Patients: A Turkish Oncology Group (TOG)Â Study.
Publication Type: Academic Journal
Source(s): Cancer investigation [Cancer Invest] 2022 Feb; Vol. 40 (2), pp. 199-209. Date of Electronic Publication: 2021 Dec 22.
Abstract: Purpose: This study evaluated the efficacy and safety of everolimus (EVE) plus exemestane (EXE) in hormone-receptor positive (HR+), human epidermal growth factor receptor-2-negative (HER2-) metastatic breast cancer (MBC) patients in real-life settings....
Phase 1 trial of entinostat as monotherapy and combined with exemestane in Japanese patients with hormone receptor-positive advanced breast cancer.
Publication Type: Academic Journal
Source(s): BMC cancer [BMC Cancer] 2021 Nov 24; Vol. 21 (1), pp. 1269. Date of Electronic Publication: 2021 Nov 24.
Abstract: Background: Entinostat is an oral inhibitor of class I histone deacetylases intended for endocrine therapy-resistant patients with hormone receptor-positive (HR+) advanced or metastatic breast cancer (BC). We examined the safety, efficacy, and pharmaco...
Effect of chronic mucus hypersecretion on treatment responses to inhaled therapies in patients with chronic obstructive pulmonary disease: Post hoc analysis of the IMPACT trial.
Publication Type: Academic Journal
Source(s): Respirology (Carlton, Vic.) [Respirology] 2022 Dec; Vol. 27 (12), pp. 1034-1044. Date of Electronic Publication: 2022 Aug 15.
Abstract: Background and Objective: Chronic mucus hypersecretion (CMH) is a clinical phenotype of COPD. This exploratory post hoc analysis assessed relationship between CMH status and treatment response in IMPACT.Methods: Patients were randomized to once-daily f...